Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMetabolism, Transport, and Pharmacogenomics

A Clearance System for Prostaglandin D2, a Sleep-Promoting Factor, in Cerebrospinal Fluid: Role of the Blood-Cerebrospinal Barrier Transporters

Masanori Tachikawa, Kazuhiro Tsuji, Reiji Yokoyama, Takanori Higuchi, Go Ozeki, Ayane Yashiki, Shin-ichi Akanuma, Kazuyuki Hayashi, Akio Nishiura and Ken-ichi Hosoya
Journal of Pharmacology and Experimental Therapeutics December 2012, 343 (3) 608-616; DOI: https://doi.org/10.1124/jpet.112.197012
Masanori Tachikawa
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiro Tsuji
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reiji Yokoyama
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takanori Higuchi
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Go Ozeki
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayane Yashiki
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin-ichi Akanuma
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuyuki Hayashi
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akio Nishiura
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken-ichi Hosoya
Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (M.T., K.T., R.Y., T.H., G.O., A.Y., S.A., K.Ho.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.T.); and Ono Pharmaceutical Co., Ltd, Osaka, Japan (K.Ha., A.N.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Although the level of prostaglandin (PG) D2 in cerebrospinal fluid (CSF) affects the action of D-type prostanoid receptors that promote physiological sleep, the regulatory system of PGD2 clearance from the CSF is not fully understood. The purpose of this study was to investigate PGD2 elimination from the CSF via the blood-CSF barrier (BCSFB). The in vivo PGD2 elimination clearance from the CSF was 16-fold greater than that of inulin, which is considered to reflect CSF bulk flow. This process was inhibited by the simultaneous injection of unlabeled PGD2. The characteristics of PGD2 uptake by isolated choroid plexus were, at least partially, consistent with those of PG transporter (PGT) and organic anion transporter 3 (OAT3). Studies using an oocyte expression system showed that PGT and OAT3 were able to mediate PGD2 transport with a Michaelis-Menten constant of 1.07 and 7.32 μM, respectively. Reverse transcription-polymerase chain reaction and immunohistochemical analyses revealed that PGT was localized on the brush-border membrane of the choroid plexus epithelial cells. These findings indicate that the system regulating the PGD2 level in the CSF involves PGT- and OAT3-mediated PGD2 uptake by the choroid plexus epithelial cells, acting as a pathway for PGD2 clearance from the CSF via the BCSFB.

Footnotes

  • This study was supported, in part, by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    http://dx.doi.org/10.1124/jpet.112.197012.

  • ABBREVIATIONS:

    PG
    prostaglandin
    PGT
    PG transporter
    L-PGDS
    lipocalin-type PGD synthetase
    [3H]PGD2
    [5,6,8,9,12,14,15-3H(N)]PGD2
    [14C]inulin
    [carboxyl-14C]inulin
    [14C]butanol
    N-[1-14C]butanol
    CSF
    cerebrospinal fluid
    BCSFB
    blood-CSF barrier
    bp
    base pairs
    DHEAS
    dehydroepiandrosterone-3-sulfate
    DP1
    D-type prostanoid receptor 1
    GLUT1
    glucose transporter 1
    HPLC
    high-performance liquid chromatography
    MRP4
    multidrug resistance-associated protein 4
    OAT
    organic anion transporter
    oatp
    organic anion transporting polypeptide
    PCR
    polymerase chain reaction
    RT
    reverse transcription
    SLC
    solute carrier.

  • Received May 30, 2012.
  • Accepted August 28, 2012.
  • Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 343 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 343, Issue 3
1 Dec 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Clearance System for Prostaglandin D2, a Sleep-Promoting Factor, in Cerebrospinal Fluid: Role of the Blood-Cerebrospinal Barrier Transporters
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMetabolism, Transport, and Pharmacogenomics

Prostaglandin D2 Clearance from the CSF

Masanori Tachikawa, Kazuhiro Tsuji, Reiji Yokoyama, Takanori Higuchi, Go Ozeki, Ayane Yashiki, Shin-ichi Akanuma, Kazuyuki Hayashi, Akio Nishiura and Ken-ichi Hosoya
Journal of Pharmacology and Experimental Therapeutics December 1, 2012, 343 (3) 608-616; DOI: https://doi.org/10.1124/jpet.112.197012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMetabolism, Transport, and Pharmacogenomics

Prostaglandin D2 Clearance from the CSF

Masanori Tachikawa, Kazuhiro Tsuji, Reiji Yokoyama, Takanori Higuchi, Go Ozeki, Ayane Yashiki, Shin-ichi Akanuma, Kazuyuki Hayashi, Akio Nishiura and Ken-ichi Hosoya
Journal of Pharmacology and Experimental Therapeutics December 1, 2012, 343 (3) 608-616; DOI: https://doi.org/10.1124/jpet.112.197012
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics